Home     Profile     Vaginitis     WH-1 Capsule     Safety & Efficacy     Clinical Trials     Business Opportunity     Contact
WH-1 A Breakthrough in the Treatment of Vaginitis
(White discharge in women)
WH-1 is an Ayurvedic Herbal Formula developed by
Dr. V.R. Bapat, Bangalore, India. For his profile click here
He has experience of treating with this formulation over
a period of 35 years in his clinical practice.

Advantages WH-1 Treatment

Single drug useful in White Discharge caused by multiple pathogens such as Bacteria, Yeast, and Trichomonas.
Useful in mixed infections
Useful in white discharge in pregnancy
Helps growth of normal vaginal flora and lactobacillus
No superimposed infection as seen in modern medicine
No adverse effects. Very safe
Cost Effective

Business Opportunity

The incidence of vaginitis in different cross sections of population is alarming. It is said that e very woman suffers from Vaginitis at least once in her lifetime. In US it is estimated that 6 million visits are made every year for treatment and over a billion dollar is spent annually on both self-treatment and visits to doctor.

The available treatment options include systemic and tropical antifungal and antibacterial agents. These medications decrease the infection temporarily but often disrupt the normal vaginal flora leading to recurrent infection and super infection by another microbe

Acute toxicity studies of WH-1 in lab animals as per OECD guidelines showed no treatment related toxicity. The product is free from heavy metals. The safety of WH-1 in human subjects has been proved by clinical studies with biochemical parameters where Kidney Function Test and Liver Function Tests were done

  WH-1 is equipotent to standard modern therapy minus all adverse effects. This single drug is useful in multiple causes of vaginitis. It does not cause side effects. In fact WH-1 causes side benefits. It increases growth of normal vaginal flora and good bacteria. (Lactobacillus)

A systematic review of CAM therapies revealed that women especially with chronic vaginal symptoms rejected antimicrobial therapies in favour of alternative remedies (96%) and these are usually educated and conscious women *

* Kessel KV, Assefi N, Marrazzo J, Eckert L Common complementary & alternative therapies for Yeast vaginitis & Bacterial vaginosis; a systematic review. Obstetrical & Gynaecological Survey.2003; 58(5):351-358.

  Drawbacks of modern treatment

The antifungal and antibacterial agents decrease the infection temporarily but often disrupt the normal vaginal flora leading to recurrent infection

Since the normal vaginal flora is altered there are chances of super infection

In a study done at St. John's Medical College many adverse reactions were noticed.


Seeking Strategic Partnership for co-development and out-licensing of an Innovative Homeopathic drugFor oral mucositis


A safe Homeo medicine for treatment of oral mucositis: -- an adverse reaction of radiotherapy and chemotherapy is available for co- development, licensing and marketing.

Oral Mucositis is the inflammation inside the mouth and throat that can lead to painful ulcers and mouth sores. It occurs in up to 40% of people receiving chemotherapy. Oral mucositis can be very painful and can significantly affect nutritional intake, mouth care, and quality of life. The majority of patients receiving radiation therapy for head and neck cancer are unable to continue eating by mouth due to mucositis pain and often receive nutrition through a gastrostomy tube or intravenous line.
Chemotherapy patients who have significant oral mucositis require supportive care measures such as use of total parenteral nutrition, fluid replacement and prophylaxis against infections. These can add substantially to the total cost of care. For example, in patients receiving chemotherapy for solid tumours or lymphoma, the estimated cost of hospitalization was $3893 per chemotherapy cycle without mucositis, $6277 per cycle with oral mucositis and $9132 per cycle with both oral and GI mucositis.
According to ‘GlobalData’, the oral mucositis therapeutics market was valued at $813.2m in 2010. The oral mucositis therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 5.2% from $813.2m in 2010 to $1,156.0m in 2017.
The current treatment option is only a palliative (but not curative) in the form of a local anaesthetic, such as a mouthwash solution that contains lidocaine or analgesics (drugs, such as acetaminophen) Tylenol.
In addition to the treatment induced Mucositis, a less severe form of oral ulcers are seen in a large section of general public. It is called Stomatitis. According to Scully and Porter, recurrent apthous stomatitis affects up to 20% of population and the most common lesion typically starts in childhood. In India it is estimated that approximately 13 million people suffer from recurrent stomatitis. 
What is the Drug?
It is a compound homeopathic formulation. For Radiation- induced mucositis it has to be given as prophylaxis one week before start of radiation and as a treatment during radiation. For stomatitis the treatment is only for 3 to 7 days. The drug can be presented in the form of tablet, gel or mouthwash.

I am using this drug successfully in acute and recurrent stomatitis since 40 years. I have anecdotal reports of its usefulness in radiation- induced oral mucositis enabling the patients to continue with radiation. The present project involves Phase-1 studies of the drug candidate and to take the research forward to marketing level. Those who are interested in this project may please contact me. Please visit my website to learn about my research aptitude.


Copyright © reserved for Dr. V.R. Bapat